Tags : Respiratory Syncytial Virus

Janssen Presented Results of RSV Vaccine in P-IIb CYPRESS Study

Tuba Khan October 4, 2021

Shots: The P-IIb CYPRESS study evaluates the efficacy & safety of RSV vaccine vs PBO in a ratio (1:1) in 5782 patients aged ≥65 with LRTD caused by RSV The […]readmore

Clinical Trials

Janssen Initiates P-III EVERGREEN Study of RSV Vaccine for the

Tuba Khan September 30, 2021

Shots: The company initiates a P-III EVERGREEN study to evaluate the efficacy, safety & immunogenicity of RSV vaccine vs PBO in 23000 adults aged ≥60yrs. with LRTD caused by RSV […]readmore

Tags : Respiratory Syncytial Virus

Janssen Presented Results of RSV Vaccine in P-IIb CYPRESS Study

Janssen Initiates P-III EVERGREEN Study of RSV Vaccine for the

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Company

Tags : Respiratory Syncytial Virus

Janssen Presented Results of RSV Vaccine in P-IIb CYPRESS Study

Janssen Initiates P-III EVERGREEN Study of RSV Vaccine for the

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Categories

Related Topics

Company